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Functional KCa3.1 K
1 channels are required for human
fibrocyte migration
Glenn Cruse, PhD,* Shailendra R. Singh, PhD,* S. Mark Duffy, PhD,* Camille Doe, BSc, Ruth Saunders, PhD,
Chris E. Brightling, PhD, and Peter Bradding, DM Leicester, United KingdomBackground: Fibrocytes are bone marrow–derived CD341
collagen I–positive cells present in peripheral blood that develop
a-smooth muscle actin expression and contractile activity in
tissue culture. They are implicated in the pathogenesis of tissue
remodeling and fibrosis in both patients with asthma and those
with idiopathic pulmonary fibrosis. Targeting fibrocyte
migration might therefore offer a new approach for the
treatment of these diseases. Ion channels play key roles in cell
function, but the ion-channel repertoire of human fibrocytes is
unknown.
Objective: We sought to examine whether human fibrocytes
express the KCa3.1 K
1 channel and to determine its role in cell
differentiation, survival, and migration.
Methods: Fibrocytes were cultured from the peripheral blood of
healthy subjects and patients with asthma. Whole-cell patch-
clamp electrophysiology was used for the measurement of ion
currents, whereas mRNA and protein were examined to confirm
channel expression. Fibrocyte migration and proliferation assays
were performed in the presence of KCa3.1 ion-channel blockers.
Results: Human fibrocytes cultured from the peripheral blood of
both healthy control subjects and asthmatic patients expressed
robust KCa3.1 ion currents together with KCa3.1 mRNA and
protein. Two specific and distinct KCa3.1 blockers (TRAM-34 and
ICA-17043) markedly inhibited fibrocyte migration in transwell
migration assays. Channel blockers had no effect on fibrocyte
growth, apoptosis, or differentiation in cell culture.
Conclusions: The K1 channel KCa3.1 plays a key role in human
fibrocyte migration. Currently available KCa3.1-channel
blockers might therefore attenuate tissue fibrosis and
remodeling in patients with diseases such as idiopathic
pulmonary fibrosis and asthma through the inhibition ofFrom the Department of Infection, Immunity and Inflammation, Institute for Lung
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Fibrocytes are bone marrow–derived CD341 collagen I–posi-
tive cells present in peripheral blood that develop a-smooth mus-
cle actin (aSMA) expression and contractile activity in tissue
culture. Their recruitment to sites of wound repair and fibrosis oc-
curs in many diseases and experimental models,1 including mu-
rine radiation- and bleomycin-induced lung fibrosis.2,3
Fibrocytes are present in human idiopathic pulmonary fibrosis
(IPF) tissue,4 and patients with IPF have 10-fold more fibrocytes
in their peripheral circulation than healthy control subjects.5 Hu-
man fibrocytes were recruited to the lungs of mice with severe
combined immunodeficiency in response to bleomycin,6 and fi-
brocytes are present in the airways of asthmatic patients.7 The
number of peripheral blood fibrocytes is increased in asthmatic
patients7 and related to the degree of airflow obstruction.8 In ad-
dition, we have identified CD341 aSMA1 cells within the airway
smooth muscle (ASM) bundles in asthmatic patients.9 Inhibiting
fibrocyte recruitment and migration therefore has great potential
for the treatment of many diverse diseases characterized by tissue
fibrosis and remodeling.
The mechanisms controlling fibrocyte migration to tissue are
poorly defined. Fibrocytes express CCR7, CXCR3, CXCR4,
CCR5, and CCR3,6,9,10 suggesting they have the potential to mi-
grate toward a number of chemokines. They also migrate in re-
sponse to the complex milieu of ASM-conditioned medium, an
effect mediated in part by platelet-derived growth factor.9 Thus
although inhibiting individual chemoattractants might attenuate
fibrocyte migration under specific circumstances, redundancy
in vivo might weaken such an approach.
Ion channels are emerging as interesting therapeutic targets in
both inflammatory and structural nonexcitable cells. Channels
carrying K1, Cl2, and Ca21 mediate a variety of cell processes,
including proliferation,11 differentiation,12 adhesion,13 mediator
release,14 and migration.15 The ion-channel repertoire of human
fibrocytes is unknown. In this study we demonstrate for the first
time that human fibrocytes express the Ca21-activated K1 chan-
nel KCa3.1 and that KCa3.1 blockade markedly attenuates fibro-
cyte migration in response to the complex milieu of human
ASM-conditioned medium and CXCL12.METHODS
Full experimental details are provided in the Methods section in this arti-
cle’s Online Repository at www.jacionline.org.1303
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Asthmawas defined as described previously.16 Healthy subjects had no his-
tory of respiratory disease. Participants were nonsmokers and free from exac-
erbations for at least 6 weeks. The Leicestershire Research Ethics Committee
approved the study (reference no. 4977). All subjects provided written in-
formed consent.Fibrocyte isolation and culture
Fibrocytes were isolated from peripheral blood and cultured as described
previously.9 Fibrocyte purity and differentiation were assessed by means of
flow cytometry and immunofluorescent staining for CD34, aSMA, and colla-
gen I, as described previously.9Quantitative real-time RT-PCR
Quantitative real-time reverse transcription PCR for KCa3.1 was performed
as previously described.17KCa3.1 protein expression
KCa3.1 protein expression was analyzed by means ofWestern blotting with
validated rabbit anti-human KCa3.1 antibodies (M20; Dr M. Chen, Glaxo-
SmithKline, Stevenage, United Kingdom)18 and P4997 (Sigma-Aldrich,
Poole, United Kingdom). KCa3.1 expression was also examined by means
of immunofluorescence with the same M20 and P4997 antibodies; the
methods are as previously described.19Patch-clamp electrophysiology
The whole-cell variant of the patch-clamp technique was used, as previ-
ously described.14Fibrocyte migration
First, we used a 24-well transwell migration assay to measure the migration
of detached differentiated fibrocytes that had been in culture for 1 week after
isolation. Cells were placed in the top of the transwell, and for the
chemoattractant in the lower chamber, we used conditioned medium from
TNF-a–activatedASMcultures. Chemokines present in thismedia include the
fibrocyte chemoattractant CXCL12.20 Cells were incubated in the presence of
chemoattractant for 4 hours, at which point cells that had migrated into the
lower well were counted by a blinded observer. Where required, the specific
KCa3.1 blockers TRAM-34 (Professor H. Wulff, University of California, Da-
vis, Calif)21 and ICA-17043 (Senicapoc; Icagen, Inc, Durham, NC)22 were
added to the top chamber before migration. These drugs did not act as chemo-
attractants when added to media in the bottom chamber.
In a further set of migration experiments, freshly isolated PBMCs
containing the immature fibrocyte populationwere allowed tomigrate through
a transwell, as described above, with the established fibrocyte chemoattractant
CXCL12 placed in the lower chamber.6 Where required, the KCa3.1 blocker
TRAM-34 was added to the top chamber before migration. After 4 hours,
the transwell was discarded, and the migrated cells were cultured for a further
7 days. The adherent cells were then fixed in 4%paraformaldehyde, stained for
collagen I, and then counted by a blinded observer.
A secondmigration assay was used to investigate the migration of adherent
elongated fibrocytes, as described previously.9Fibrocyte growth and maturation
Fibrocytes were incubated with TRAM-34 (20-2000 nmol/L) either from
days 0 to 7 or from days 7 to 14 after isolation. Cells were then harvested and
counted. In addition, the MTS proliferation assay was performed. Parallel
chamber slides were examined to look at fibrocyte morphology and differen-
tiation markers, as previously described.9Quantification of cell death
Fibrocytes were incubated with TRAM-34 at a dose range of 20 to 2000
nmol/L in their normal growth medium, either from days 0 to 7 after isolation
or from days 7 to 14. Cells were analyzed by means of flow cytometry for the
presence of early apoptotic and late apoptotic cells.Statistics
Experiments were performed in duplicate, and a mean value was derived
for each condition. For all assays, across-group differences were analyzed by
means of ANOVA, and inhibition of migration was analyzed by using a paired
t test. Patch-clamp data were analyzed by using paired or unpaired t tests, as
appropriate.RESULTS
Human fibrocytes express KCa3.1 mRNA and protein
Fibrocyte cell cultures developed the typical morphology and
immunologicmarkers of human fibrocytes.9 All fibrocyte cultures
assessed by quantitative real-time reverse transcription PCR
(n 5 6 healthy subjects, n 5 3 asthmatic patients) expressed
KCa3.1 mRNA (Fig 1, A). However, there was no difference in
KCa3.1 mRNA expression between healthy subjects and asth-
matic patients by using the mean KCa3.1 cycle threshold/b-actin
cycle threshold values (mean 6 SEM: healthy subjects, 0.604 6
0.023 [n5 6]; asthmatic patients, 0.6066 0.022 [n5 3]). Fibro-
cyte lysates contained a KCa3.1 immunoreactive protein of ap-
proximately 53 kd in molecular weight (Fig 1, B), which is
close to the predicted size of 47 kd and similar to the previously
reported size of 53 kd for KCa3.1 in Western blots.
17,18 This was
identified by both the M20 KCa3.1 antibody, which targets the N
terminus (n5 9 subjects), and the P4997 antibody, which targets
the C terminus (n 5 3 subjects). P4997 also produced a band of
approximately 65 kd of uncertain significance. KCa3.1 immunore-
activity was also evident in fixed cultured fibrocytes by using both
KCa3.1 antibodies (Fig 1, C).Human fibrocytes express heterogeneous ion
currents at ‘‘rest’’
At baseline, immediately after obtaining the whole-cell patch-
clamp configuration, unstimulated fibrocytes (n 5 30 healthy
cells from 7 donors and n 5 17 asthmatic cells from 4 donors)
demonstrated heterogeneity of the resting whole-cell current,
with a small outwardly rectifying current in 91% of cells, a
steeply inwardly rectifying current characteristic of the Kir2.0
family of channels in 30% of cells, and a linear current in 9% of
cells (Fig 2). The outwardly rectifying current was not altered by
substitution of external Cl2 (data not shown) andmight be carried
by a nonselective cation channel, such as the ubiquitous transient
receptor potential channel 7.23 Mean reversal potential for the
whole population of cells (n 5 47) at baseline was 229.8 6 3.0
mV. Mean baseline whole-cell current at 140 mV was 122 6
25 pA, and there was no difference in the size of the baseline cur-
rent or reversal potential in cells from healthy compared with
FIG 1. KCa3.1 mRNA and protein expression in fibrocytes. A, Real-time RT-
PCR demonstrating KCa3.1 mRNA expression in fibrocytes from 1 healthy
and 1 asthmatic donor. Data are representative of results from 9 donors.
B,Western blotting for KCa3.1 (P4997 antibody) in healthy (N) and asthmatic
(A) fibrocytes demonstrating bands of approximately 53 kd. *Same donor.
C, Immunofluorescent staining (M20 antibody) for KCa3.1 in cultured fibro-
cytes (left panel) demonstrating strong immunoreactivity. Results of iso-
type control staining were negative (right panel).
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carried by the voltage-dependent K1 channel Kv1.3, which is
found in resting T cells.24
Measurements of fibrocyte capacitance were unreliable be-
cause of the relatively large cell size. However, cell size assessed
by means of flow cytometry was similar between donors (mean6
SEM: 4891 6 158 arbitrary units [n 5 13 donors]) and between
healthy control subjects compared with asthmatic patients
(P 5 .60).Human fibrocytes express robust KCa3.1 ion
currents
To elicit KCa3.1 currents, we used the KCa3.1 opener 1-ethyl-2-
benzimidazolinone (1-EBIO; Tocris, Avonmouth, United King-
dom), as described previously.17,25,26 This compound opens
KCa3.1 with a half-maximal value of about 30 mmol/L for heter-
ologously expressed KCa3.1.
27
Addition of 1-EBIO (100 mmol/L) elicited a typical KCa3.1
current in 46 of 47 cells tested (from 7 healthy and 4 asthmatic do-
nors; Fig 3, A-C). Whole-cell current at140mVincreased from a
mean 6 SEM of 122 6 25 pA before 1-EBIO to 795 6 104 pA
after 1-EBIO (P < .0001; Fig 3, C) accompanied by a negativeshift in reversal potential from 229.8 6 3.0 mV to 261.8 6
1.6 mV (P < .0001; Fig 3, D). 1-EBIO induced a greater current
in fibrocytes from asthmatic patients (1-EBIO–dependent current
at140 mV 5 9696 216 pA [n 5 17 cells]) compared with that
seen in fibrocytes from healthy subjects (1-EBIO–induced
current 5 506 6 94 pA [n 5 30 cells], P 5 .029), but there was
no difference in reversal potential (P 5 .352).
The 1-EBIO–induced current demonstrated the classical elec-
trophysiological features of KCa3.1: it appeared immediately as
voltage steps were applied, did not decay during a 100-ms pulse,
and demonstrated inward rectification from membrane potentials
positive to about140 mV (Fig 3, A and B). Furthermore, the cur-
rent was completely blocked by the selective KCa3.1 blockers
TRAM-34 (concentration producing 50% block [Kd], 20 nmol/
L)21 and ICA-17043 (Kd, approximately 10 nmol/L)
22 at concen-
trations of 200 and 100 nmol/L, respectively (Fig 3, E and F).
See the Results section in this article’s Online Repository at
www.jacionline.org for statistical analysis. The reversal poten-
tials after addition of TRAM-34 and ICA-17043 (in the presence
of 1-EBIO) were significantly more positive (P5 .0018 and P5
.0016, respectively) than the respective baseline values, indicat-
ing the presence of open KCa3.1 channels at rest. In summary, hu-
man fibrocytes express robust KCa3.1 currents.KCa3.1 channels do not regulate fibrocyte growth,
maturation, or survival
Incubation of developing fibrocyte cultures with TRAM-34
(20-2000 nmol/L) at days 0 to 7 or days 7 to 14 after isolation had
no significant effect on cell number (Fig 4, A and B), proliferation
(Fig 4, C and D), cell morphology, expression of fibrocyte
markers (Fig 4, E), or early and late apoptosis (Fig 4, F-I).Functional KCa3.1 channels are required for human
fibrocyte migration
ASM supernatants stimulated with TNF-a induced the migra-
tion of differentiated 1-week-old fibrocytes (Fig 5,A), withmigra-
tion 2.4 6 0.2–fold greater than control medium (n 5 9 donors,
P < .0001). The KCa3.1-specific blocker TRAM-34 markedly in-
hibited the ASM-induced fibrocyte migration dose dependently
(Fig 5, B). Thus with 200 nmol/L TRAM-34 (Kd, 20 nmol/L),
21
ASM-induced migration was reduced by 70.7% 6 6.2% (n 5
9, P < .0001). ASM-induced fibrocyte migration was also in-
hibited by the distinct and specific KCa3.1 blocker ICA-17043
(Kd, approximately 10 nmol/L),
22 with migration reduced by
63.8% 6 17.8% at a concentration of 100 nmol/L (n 5 5, P 5
.023). Freshly isolated fibrocytes/precursors within a PBMC pop-
ulationmigrated in response to CXCL12 (fold change, 3.96 1.0),
and this wasmarkedly inhibited by 200 nmol/LTRAM-34 (82.9%
6 4.4% inhibition, P 5 .0001 across groups; Fig 5, C).
Migration of adherent elongated fibrocytes was a mean of 25.1
6 0.9 mm from the point of origin over 4.5 hours. This was not
inhibited by TRAM-34 or ICA-17043 (n 5 7 donors and n 5 3
donors, respectively).DISCUSSION
This is the first study to examine ion channel expression in
human fibrocytes. The key finding is that human fibrocytes
express the calcium-activated K1 channel KCa3.1 and that
FIG 2. Heterogeneity of resting whole-cell currents in human fibrocytes. Example current-voltage (I/V)
curves (top panels) and raw current (bottom panels) of an inwardly rectifying current (A), a linear current (B),
and an outwardly rectifying current (C) are shown.
FIG 3. Human fibrocytes express robust KCa3.1 currents. A, Current-voltage (I/V) curve of a fibrocyte at base-
line and after addition of the KCa3.1 opener 1-EBIO (100 mmol/L). 1-EBIO induces a large whole-cell current
characteristic of KCa3.1, with an accompanying negative shift in reversal potential (arrow). B, Characteristic
KCa3.1 raw current from the same cell as in Fig 3, A, after 1-EBIO. The dotted line represents zero current at
reversal potential. Inset, Voltage protocol. C, Whole-cell current measured at 140 mV in fibrocytes from
healthy (open circles) and asthmatic (solid circles) subjects at baseline and after addition of 1-EBIO (100
mmol/L). D, Reversal potential in fibrocytes from healthy (open circles) and asthmatic (solid circles) subjects
at baseline and after addition of 1-EBIO. E, Block of KCa3.1 whole-cell currents by TRAM-34 (200 nmol/L) with
an accompanying positive shift in reversal potential (arrow). Mean 6 SEM of 18 cells recorded. F, Block of
KCa3.1 whole-cell currents by ICA-17043 (100 nmol/L) with an accompanying positive shift in reversal
potential (arrow). Mean 6 SEM of 8 cells recorded.
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induced by the complex milieu of TNF-a–activated ASM super-
natant and the chemokine CXCL12.
Expression of both KCa3.1 mRNA and protein was evident in
fibrocytes, and importantly, functional channels revealed by
means of patch-clamp electrophysiology were present in the
plasma membrane. Large KCa3.1 currents were present in 98%of cells tested, and this distinguishes fibrocytes from related
ASM cells, which only express consistent currents after incuba-
tion with growth factors.17 KCa3.1 whole-cell currents were
larger in cells from asthmatic patients compared with healthy
control subjects, although mRNA and protein expression were
similar. The biological significance of this requires further
investigation.
FIG 5. KCa3.1 blockade inhibits human fibrocyte migration. A, Migration of
cultured, 1-week-old detached fibrocytes through an 8-mm pore-size trans-
well membrane was significantly enhanced when conditioned media from
TNF-a–stimulated ASM (ASM S/N) was added to the bottom chamber.
Values are presented asmeans6 SEMs from 9 donors. ***P < .0001, paired
t test. B, Fibrocyte migration was significantly attenuated by the KCa3.1
blockers TRAM-34 and ICA-17043. ASM-dependent migration in Fig 5, A,
is represented as 100% in Fig 5, B. Dimethyl sulfoxide (DMSO) 0.1% was
present in all conditions. Values are means 6 SEMs from 9 donors. P <
.0001 across groups, ANOVA. *P < .05, **P < .01, and ***P < .0001, paired
t test. C, Migration of freshly isolated fibrocytes/precursors in a PBMC prep-
aration in response to CXCL12 is markedly attenuated by TRAM-34 (200
nmol/L). After 4 hours of migration, the cells were cultured for 1 week,
stained for collagen I, and then counted. Values are mean 6 SEMs from 7
donors. P 5 .0053 across conditions, ANOVA. #P 5 .003. *P < .0001, paired
t test.
FIG 4. KCa3.1 blockade does not affect fibrocyte growth, differentiation, or
survival. A and B, Fold increase (over control media) in the number of fibro-
cytes incubated with dimethyl sulfoxide (DMSO) control and TRAM-34 (20-
2000 nmol/L) from days 0 to 7 (Fig 4, A) and from days 7 to 14 (Fig 4, B) after
isolation (n 5 7 donors). Values are expressed as means 6 SEMs. C and D,
Cell proliferation and viability assessed by using the MTS assay in fibro-
cytes incubated with DMSO control and TRAM-34 (20-2000 nmol/L) from
days 0 to 7 (Fig 4, C) and from days 7 to 14 (Fig 4, D). Data are presented
as the mean fold increase over the media control 6 SEM (n 5 3). E, Fibro-
cyte morphology after 7 days in control conditions (left panels) or with
TRAM-34 (200 nmol/L, right panels) is similar. Cells in both conditions ex-
press the typical spindle-like morphology and express the fibrocyte
markers collagen I (top panels) and aSMA (lower panels, representative
of 2 independent experiments). F-I, Apoptosis was assessed by means of
flow cytometry with fluorescein isothiocyanate–Annexin V/propidium io-
dide binding in fibrocytes incubated with control media, DMSO control,
and TRAM-34 (20-2000 nmol/L) from days 0 to 7 and from days 7 to 14.
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tion of several cell types, including mast cells,15 glial cells,28
NIH3T3 fibroblasts,29 and melanoma cells.29 The proposed
mechanism is that KCa3.1 activity is required for detachment
of the uropod through the regulation of cell volume and actin dy-
namics.30 In keeping with this, KCa3.1 blockade with the 2 dis-
tinct and specific channel blockers TRAM-34 and ICA-17043
resulted in a marked inhibition of fibrocyte migration in trans-
well migration assays. This was evident when fibrocyte migra-
tion was analyzed in both freshly isolated cells within a
PBMC preparation and differentiated cells that had been cul-
tured for 1 week. Importantly, the ion-channel blockers inhibited
migration at physiologically relevant concentrations. Thus it
takes 5 to 10 times the Kd to inhibit all channels. The Kd for
TRAM-34 is 20 nmol/L,21 and that for ICA-17043 is 6 to 10
nmol/L.22 At 10 times the Kd for both blockers, migration was
markedly inhibited, and at these concentrations, both drugs are
highly specific for KCa3.1.
22,31
Interestingly, KCa3.1 blockade only inhibited fibrocyte migra-
tion when the cells were freshly isolated or had been detached
and were thus ‘‘rounded’’ in shape, although not when the cells
were adherent and elongated. This has several potential
explanations.
First, migration of adherent fibrocytes is relatively poor
compared with that of other cells, such as eosinophils, in
2-dimensional and 3-dimensional assays.9,32 Thus the propensity
for fibrocytes to migrate might be greater when ‘‘detached,’’ thus=
Percentage of early apoptotic fibrocytes revealed by Annexin V1 (Fig 4, F:
days 0-7; Fig 4, H: days 7-14) and late apoptotic cells revealed by Annexin
V1/propidium iodide–positive cells (Fig 4, G: days 0-7; Fig 4, I: days 7-14)
of 3 fibrocytes incubated with relevant conditions. Data are presented as
means 6 SEMs.
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cause peripheral blood fibrocytes need to move through the endo-
thelium to their tissue destination and might only develop their
adherent morphology once they reach their goal. In keeping
with this, fibrocytes present in human bronchial mucosa 24 hours
after allergen challenge have a rounded morphology.33 In con-
trast, fibrocytes present in the airway mucosa from patients with
chronic asthma and murine airway mucosa 6 weeks after antigen
challenge have the adherent morphology.9,33
Second, the signaling pathways for migration might be differ-
ent in detached fibrocytes compared with those in adherent
elongated cells. This is supported by the finding that migration of
both freshly isolated and cultured detached fibrocytes is inhibited
by KCa3.1 blockers but that of adherent cells is not.
T cells also express KCa3.1 and were present as a contaminant
in our fibrocyte cultures. However, KCa3.1 expression in quies-
cent T cells is relatively low at approximately 20 channels per
cell.24 Thus although T cells might potentially contribute to the
PCR signal we demonstrated, they would not account for the pos-
itive KCa3.1 staining in Western blotting and immunofluorescent
microscopy. Fibrocytes and T cells were readily distinguishable
by size, which is validated by the fact that we never recorded a
characteristic T-cell Kv1.3 current when patch clamping. There-
fore although occasional T cells were evident in the migration as-
says performed on 1-week-old cultured fibrocytes, these were
readily apparent and did not complicate the analysis. Thus we
are confident that the functional effects we attribute to KCa3.1
in human fibrocytes are not confounded by the presence of con-
taminating T cells.
Increasing evidence indicates that fibrocytes play an important
role in tissue remodeling and fibrosis in both the lung2-9 and a va-
riety of other organs.1,6,34 Strategies that inhibit fibrocyte migra-
tion might therefore attenuate fibrotic disease. Several
chemokines have been identified as fibrocyte chemoattractants,
but targeting these might be ineffective because of extensive re-
dundancy.35 A less selective approachmight therefore bemore ef-
fective. KCa3.1 blockade inhibits cell migration to a number of
diverse stimuli15 and inhibited fibrocyte migration to the complex
milieu of activated ASM supernatant, as well as CXCL12. This
suggests that KCa3.1 blockade might be particularly effective at
inhibiting fibrocyte migration in vivo.
KCa3.1 is an attractive pharmacologic target because its block-
ade does not have major adverse effects on normal physiology.
KCa3.1 knockout mice are viable and of normal appearance, pro-
duce normal litter sizes, and exhibit rather mild phenotypes.36-38
High doses of TRAM-34 administered to mice over many weeks
are well tolerated,39 and the orally available KCa3.1 blocker ICA-
17043 has been administered to human subjects in phase 2 and 3
trials of sickle cell disease with minor side effects.40
In summary, human fibrocytes express the K1 channel KCa3.1,
which is a key regulator of in vitro fibrocyte migration. KCa3.1
blockade may therefore attenuate tissue fibrosis and remodeling
in diseases in which fibrocytes play a role, such as IPF and asthma.
The availability of a well-tolerated, orally bioavailable KCa3.1
blocker means that this can be tested readily in human clinical
trials.
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d Fibrocytes play a key role in tissue remodeling and fibro-
sis in patients with diseases such as asthma and pulmo-
nary fibrosis. Ion channels are interesting therapeutic
targets for the modulation of cell function.
d This is the first investigation of human fibrocyte ion
channel expression and demonstrates the presence of
functional KCa3.1 K
1 channels. Activity of these channels
is required for fibrocyte migration.
d Inhibition of KCa3.1 ion channels might reduce airway
and parenchymal fibrosis in patients with asthma and
pulmonary fibrosis, respectively. The availability of an
orally bioavailable KCa3.1 blocker means that this can
be tested readily in human clinical trials.
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Subjects
Healthy control subjects and patients with asthma were recruited from
respiratory clinics and hospital staff and by means of local advertising.
Asthma was defined by using standard criteria, as described previously.E1
Healthy subjects had no history of respiratory disease. All subjects were non-
smokers with a past smoking history of less than 10 pack-years and were free
from exacerbations for at least 6 weeks. The Leicestershire Research Ethics
Committee approved the study (reference no. 4977). All patients provided
written informed consent.
Cell isolation and culture
Fibrocytes were isolated from peripheral blood and cultured in fibronectin-
coated T25 tissue-culture flasks, as described previously.E2 After 48 hours,
nonadherent cells were removed. After 7 to 14 days, adherent cells were
washed with Hanks’ balanced salt solution and harvested with Accutase
(eBioscience,Wembley, UnitedKingdom). Cell counts and viability of the ini-
tial isolated PBMC fraction and the final adherent cells were determined by
using trypan blue stain. Viability was consistently greater than 95%. In paral-
lel, PBMC preparations were seeded onto fibronectin-coated 8-well chamber
slides (23 105 cells per well) and cultured as above. Fibrocyte purity and dif-
ferentiation were assessed by means of flow cytometry and immunofluores-
cent staining for CD34, aSMA, and collagen I, as described previously.E2
Fibrocyte purity was routinely greater than 95%, with morphologically dis-
tinct T cells accounting for the contaminants.
Quantitative real-time RT-PCR
Quantitative real time RT-PCR was performed as described previously.E3
Briefly, the following primers for KCa3.1 were used (forward primer, 59-GGA-
CATCTCCAAGATGCACA-39; reverse primer, 59-AGGAGTGGCAGA-
GACGATGT-39). The internal normalizer gene used was b-actin (forward
primer, 59-TTCAACTCCATCATGAAGTGTGACGTG-39; reverse primer,
59-CTAAGTCATAGTCCGCCTAGAAGCATT-39). All KCa3.1 expression
data were normalized to b-actin and corrected by using the reference dye
(ROX). Briefly, PCR was performed with a single-tube Full Velocity SYBR
green kit (Stratagene, Amsterdam, The Netherlands). Only experiments in
which a distinct single peakwas observedwith amelting temperature different
than that of the no-template control were used. The level of expression be-
tween donors was calculated by the cycle threshold of the gene of interest/
cycle threshold of the internal normalizing gene.
Analysis of KCa3.1 protein expression
KCa3.1 protein expression was analyzed by means of Western blotting, as
previously described.E4 Soluble protein from equivalent numbers of cells
was resolved by using 12%SDS-PAGE and then transferred to a nitrocellulose
membrane. Membranes were blocked and incubated with validated primary
rabbit anti-human KCa3.1 antibodies (M20; a gift from Dr M. Chen, Glaxo-
SmithKline)E5 and P4997 (Sigma-Aldrich). Protein bands were identified by
means of horseradish peroxidase–conjugated secondary antibody (DAKO,
Cambridge, United Kingdom) and ECL reagent (Amersham, Little Chalfont,
United Kingdom).
KCa3.1 expression was also examined by means of immunofluorescence
with the same M20 and P4997 antibodies, with methods as described
previously.E4
Patch-clamp electrophysiology
The whole-cell variant of the patch-clamp technique was used.E6,E7 Patch
pipettes were made from borosilicate fiber–containing glass (Clark Electro-
medical Instruments, Reading, United Kingdom), and their tips were heat
polished, typically resulting in resistances of 4 to 6 MU. The standard pipette
solution contained 140 mmol/L KCl, 2 mmol/L MgCl2, 10 mmol/L
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 2 mmol/L
Na1-ATP, and 0.1 mmol/L guanosine triphosphate (pH 7.3). The standard ex-
ternal solution contained 140 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L CaCl2,
1 mmol/L MgCl2, and 10 mmol/L HEPES (pH 7.3). For recording, fibrocyteswere placed in 35-mm dishes containing standard external solution. Whole-
cell currents were recorded with an Axoclamp 200A amplifier (Axon Instru-
ments, Foster City, Calif), and currents were evoked by applying voltage
commands to a range of potentials in 10-mV steps from a holding potential
of 220 mV. The currents were digitized (sampled at a frequency of 10
kHz), stored on computer, and subsequently analyzed with pClamp software
(Axon Instruments). Capacitance transients were minimized by using the ca-
pacitance neutralization circuits on the amplifier. Correction for series resis-
tance was not routinely applied. Experiments were performed at 278C, and
the temperature was controlled with a Peltier device. Experiments were per-
formed with a perfusion system (Automate Scientific, San Francisco, Calif)
to allow solution changes, although drugs were added directly to the recording
chamber.
Fibrocyte migration
First, we used a 24-well transwell migration assay to measure the migration
of detached differentiated fibrocytes that had been in culture for 1 week after
isolation. The transwell inserts were coated with 40 mg/mL fibronectin for
1 hour at 378C. Chemoattractant was added to the bottom compartment of each
well, with the exception of the negative controls. For the chemoattractant, we
used 425mLof conditionedmedium fromASMcultures that had been activated
for 24 hourswith 10 ng/mLTNF-a. Chemokines present in thismedium include
the fibrocyte chemoattractant CXCL12.E8 The ASM supernatant was supple-
mented with 5% serum. Fibrocyte cultures were thoroughly washed several
timeswith freshmedium to remove nonadherent cells. Cultures were then tryp-
sinized, and 13 105 fibrocytes were added to the top chamber of each well in
duplicate. Cells were incubated in the presence of chemoattractant for 4 hours,
at which point the cells present in the lower well were recovered by means of
pipetting, transferred to a 96-wellV-bottomplate, centrifuged at 250g for 5min-
utes, and then resuspended in Kimura stain for counting with a hemocytometer
by a blinded observer. Pilot studies demonstrated that fibrocytes were readily
distinguishable from sparse (<5% ofmigrating cells) T cells based onmorphol-
ogy, did not adhere to the underside of the transwell membrane, and did not re-
main adherent to the lower chamber in the short term after pipetting. Where
required, the specific KCa3.1 blockers TRAM-34 (a gift from Professor H.
Wulff, University ofCalifornia,Davis, Calif)E9 and ICA-17043 (a gift from Ica-
gen, Inc)E10 were added to the top chamber before migration.
In a further set of migration experiments, freshly isolated PBMCs
containing the fibrocyte population were allowed to migrate through a
transwell, as described above (13 107 cells/top chamber), with the established
fibrocyte chemoattractant CXCL12E11 placed in the lower chamber.Where re-
quired, the KCa3.1 blocker TRAM-34was added to the top chamber beforemi-
gration. After 4 hours, the transwell was discarded, and themigrated cells were
cultured for 24 hours, washed to remove nonadherent cells, and then cultured
for a further 6 days. The cells were thenwashed 3 times to remove nonadherent
cells, and the remaining adherent cells were fixed in 4% paraformaldehyde,
stained for collagen I, and then counted by a blinded observer.
A second migration assay was used to investigate the migration of adherent
elongated fibrocytes, as described previously.E2 ASMcells (2.53 105 cells per
well) were seeded onto fibronectin-coated (1mg/mL) 8-rectangular-well plates
and allowed to adhere overnight before removal by scraping of half the ASM
below a predrawn line on the well underside. Fibrocytes (4-8 3 104 cells per
well) were then added for 72 hours before pretreatment with the specific
KCa3.1 blockers TRAM-34 and ICA-17043 for 1 hour before migration track-
ing began. Photographs of the fibrocytes were taken along a predrawn line 5
mmbelow the edge of themulticell layer or equivalent position in control wells
at 1.5-hour intervals over a 4.5-hour time course. The migration of individual
fibrocytes was tracked manually, and both the distance of migration and the
percentage of cells migrating were measured by a blinded observer.
Fibrocyte growth and maturation
Fibrocytes were incubated with TRAM-34 at a dose range of 20 to 2000
nmol/L in their normal growthmedium, either fromdays 0 to 7 after isolation or
from days 7 to 14 after isolation. Cells were then harvested and counted with a
hemocytometer. In addition, the MTS proliferation assay was performed.
Fibrocytes were cultured at a density of 23 103 cells per well in flat-bottomed
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Fibrocytes were then incubated with or without TRAM-34 (dose range, 20-
2000 nmol/L) in their normal growth medium for a further 7 days. Next,
20mLofCellTiter 96AqueousOneSolution Reagent (Promega, Southampton,
United Kingdom) was added to each well. After 4 hours in culture, the cell vi-
ability was determined by measuring the absorbance at 490 nm with a Wallac
VictorE2 1420multilabel counter (PerkinElmer, Cambridge, UnitedKingdom).
Parallel chamber slides were examined to examine fibrocyte morphology
and differentiation markers, as described previously.E2
Quantification of cell death by means of flow
cytometry
After isolation, fibrocyteswere incubatedwith TRAM-34 at a dose range of
20 to 2000 nmol/L in their normal growthmedium, either fromdays 0 to 7 after
isolation or from days 7 to 14. Fibrocytes were harvested by means of
trypsinization to determine the percentage of apoptotic or necrotic cells. Next,
these cells were suspended in Annexin-binding buffer containing fluorescein
isothiocyanate–conjugated Annexin V (5 mL/300 mL of binding buffer; BD
PharMingen, San Jose, Calif), followed by counterstaining with or without
propidium iodide (0.5 mg/mL), before processing on the BD FACSCanto flow
cytometer (BD Biosciences, Oxford, United Kingdom). The intensity of
stainingwas determined for 10,000 cells in each assay. Thereafter, the samples
were analyzed by means of flow cytometry for the presence of early apoptotic
(only Annexin V positive) and late apoptotic (double positive for Annexin V
and propidium iodide) cells.
Statistics
Experiments were performed in duplicate, and a mean value was derived
for each condition. For all assays, across-group differences were analyzed by
means of ANOVA, and inhibition of migration was analyzed by using the
paired t test. Patch-clamp data were analyzed by using paired or unpaired t
tests, as appropriate.
RESULTS
Human fibrocytes express robust KCa3.1 ion
currents
To elicit KCa3.1 currents, we used the KCa3.1 opener 1-EBIO
(Tocris, Avonmouth, United Kingdom), as described previously
in human lung mast cellsE12,13 and ASM cells.E3 This compound
opens KCa3.1 with a half-maximal value of about 30 mmol/L for
heterologously expressed KCa3.1, with a maximal effect at 300
mmol/L.E14
Addition of 1-EBIO (100 mmol/L) elicited a typical KCa3.1
current in 46 of 47 cells tested (7 healthy and 4 asthmatic donors).
Whole-cell current at 140 mV increased from a mean 6 SEM
of 122 6 25 pA before 1-EBIO to 795 6 104 pA after 1-EBIO
(P < .0001). This was accompanied by a negative shift in reversal
potential from229.86 3.0 mV to261.86 1.6 mV (P < .0001).
1-EBIO induced a greater current in fibrocytes from asthmatic
patients (1-EBIO–dependent current at 140 mV 5 969 6 216
pA [n 5 17 cells]) compared with fibrocytes from healthy sub-
jects (1-EBIO–induced current 5 506 6 94 pA [n 5 30 cells],
P 5 .029), but there was no difference in reversal potential
(P 5 .352).
The 1-EBIO–induced current demonstrated the classical
electrophysiological features of KCa3.1 in that it appeared imme-
diately as voltage steps were applied, did not decay during a
100-ms pulse, and demonstrated inward rectification from mem-
brane potentials positive to about140 mV. Furthermore, the cur-
rent was completely blocked by the selective KCa3.1 blockers
TRAM-34E9 and ICA-17043E10 at concentrations of 200 and
100 nmol/L, respectively. Thus 1-EBIO–induced current at 140mV was reduced from 984 6 226 pA after 1-EBIO to 171 6
64 pA after 200 nmol/L TRAM-34 (n 5 18 cells, P 5 .0005),
with a positive shift in reversal potential from 265.4 6 1.7 mV
after 1-EBIO to 212.7 6 2.3 mV after TRAM-34 (P < .0001).
With ICA-17043, the 1-EBIO2induced current at 140 mV re-
duced from 774 6 203 pA to 128 6 52 pA after 100 nmol/L
ICA-17043 (n5 8 cells, P5 .0072), with a shift in reversal poten-
tial from259.36 4.5 mVafter 1-EBIO to212.56 6.7 mVafter
ICA-17043 (P5 .0016). The reversal potentials after addition of
TRAM-34 and ICA-17043 (in the presence of 1-EBIO) were sig-
nificantly more positive (P 5 .0018 and P 5 .0016, respectively)
than the respective baseline values, indicating the presence of
open KCa3.1 channels at rest. In summary, human fibrocytes ex-
press robust KCa3.1 currents.
In keeping with previous findings in human lung mast cells, in
which we studied CXCL10,E15 KCa3.1 was not opened in fibro-
cytes by the chemokine CXCL12. This indicates that the gating
of KCa3.1 during fibrocyte migration is downstream of the chemo-
attractant stimulus, most probably related to adhesive signals re-
quired for the migratory process.
